INSM Stock Recent News

INSM LATEST HEADLINES

INSM Stock News Image - zacks.com

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insmed (INSM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.

zacks.com 2025 Feb 17
INSM Stock News Image - zacks.com

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com 2025 Feb 13
INSM Stock News Image - prnewswire.com

BRIDGEWATER, N.J. , Feb. 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: 45th Annual TD Cowen Healthcare Conference in Boston, on Monday, March 3, 2025, at 9:10 a.m.

prnewswire.com 2025 Feb 11
INSM Stock News Image - prnewswire.com

BRIDGEWATER, N.J. , Feb. 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its fourth-quarter and full-year 2024 financial results on Thursday, February 20, 2025.

prnewswire.com 2025 Feb 10
INSM Stock News Image - seekingalpha.com

Insmed's Arikayce, a treatment for MAC and NTM lung diseases, generated $93.4m in Q3 2023, with full-year revenue guidance of $340m-$360m. Brensocatib, Insmed's lead pipeline candidate for non-CF bronchiectasis, received FDA Priority Review with a target action date of August 12, 2025. This is a potential multi-billion dollar selling asset. Brensocatib's market potential is significant, with Wall Street analysts projecting peak annual revenues exceeding $5bn, bolstering Insmed's market cap of $14.45bn.

seekingalpha.com 2025 Feb 07
INSM Stock News Image - zacks.com

The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.

zacks.com 2025 Feb 07
INSM Stock News Image - prnewswire.com

BRIDGEWATER, N.J. , Feb. 7, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 66 new employees.

prnewswire.com 2025 Feb 07
INSM Stock News Image - prnewswire.com

—Brensocatib Would be the First and Only Available Treatment for Bronchiectasis and First DPP1 Inhibitor, if Approved— BRIDGEWATER, N.J. , Feb. 6, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for brensocatib for patients with non-cystic fibrosis bronchiectasis.

prnewswire.com 2025 Feb 06
INSM Stock News Image - prnewswire.com

--ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately  $363.7 Million-- --2025 Global ARIKAYCE Revenues Expected to be Between $405 Million and $425 Million, Reflecting Continued Double-Digit Growth Compared to 2024-- --NDA for Brensocatib in Bronchiectasis Submitted to FDA in December 2024, Narrowing the Timing for Expected U.S. Launch to the Third Quarter of 2025, Pending Approval Under Priority Review-- --Enrollment for Phase 2 Study of TPIP in Patients with PAH Completed in December 2024; Expected Timing for Topline Data Moved Forward to Mid-2025-- --Phase 3 ENCORE Trial for ARIKAYCE in Patients with Newly Diagnosed or Recurrent MAC Lung Disease Fully Enrolled; Topline Data Anticipated in First Quarter of 2026-- --IND Cleared for Insmed's First Gene Therapy (INS1201) for Patients with DMD; First Patient Dosing Anticipated in the First Half of 2025-- BRIDGEWATER, N.J. , Jan

prnewswire.com 2025 Jan 10
INSM Stock News Image - prnewswire.com

BRIDGEWATER, N.J. , Jan. 3, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 19 new employees.

prnewswire.com 2025 Jan 03
10 of 50